Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Treatment for hepatitis C virus-associated mixed cryoglobulinaemia.
Montero N, Favà A, Rodriguez E, Barrios C, Cruzado JM, Pascual J, Soler MJ. Montero N, et al. Cochrane Database Syst Rev. 2018 May 7;5(5):CD011403. doi: 10.1002/14651858.CD011403.pub2. Cochrane Database Syst Rev. 2018. PMID: 29734473 Free PMC article. Review.
Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. SELECTION CRITERIA: All randomised controlled trials (RCTs) and quasi-R …
Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical …
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials.
Matos I, Villacampa G, Hierro C, Martin-Liberal J, Berché R, Pedrola A, Braña I, Azaro A, Vieito M, Saavedra O, Gardeazabal I, Hernando-Calvo A, Alonso G, Galvao V, Ochoa de Olza M, Ros J, Viaplana C, Muñoz-Couselo E, Elez E, Rodon J, Saura C, Macarulla T, Oaknin A, Carles J, Felip E, Tabernero J, Dienstmann R, Garralda E. Matos I, et al. Eur J Cancer. 2021 Sep;155:168-178. doi: 10.1016/j.ejca.2021.05.040. Epub 2021 Aug 9. Eur J Cancer. 2021. PMID: 34385069 Free article. Clinical Trial.
RESULTS: We recruited 799 patients (training and validation sets, 558 and 241, respectively). Median follow-up was 21.2 months (m), mOS was 10.2 m (95% CI, 9.3-12.7) for ICIs cohort and 7.7 m (95% CI, 6.6-8.6) for TAs cohort. ...
RESULTS: We recruited 799 patients (training and validation sets, 558 and 241, respectively). Median follow-up was 21.2 months (m), m …
Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
Riudavets M, Bosch-Barrera J, Cabezón-Gutiérrez L, Diz Taín P, Hernández A, Alonso M, Blanco R, Gálvez E, Insa A, Mielgo X, Morán T, Ponce S, Roa D, Sánchez JM, Majem M. Riudavets M, et al. Clin Transl Oncol. 2021 Dec;23(12):2560-2567. doi: 10.1007/s12094-021-02661-2. Epub 2021 Jul 22. Clin Transl Oncol. 2021. PMID: 34292495
The most common EGFR mutations were exon 19 deletion (52.6%) and exon 21 L858R mutation (36.8%); 47.4% patients presented the EGFR T790M. 94.8% of the patients had received 2-3 previous treatment lines. Docetaxel was administered at 75 mg/m(2)/3 weeks to 16 patients, at 60 …
The most common EGFR mutations were exon 19 deletion (52.6%) and exon 21 L858R mutation (36.8%); 47.4% patients presented the EGFR T790M. 94 …